The Ghost of Martin Shkreli Still Haunts Drug Prices

It’s Shkreli redux.

 The Financial Times reported Tuesday that a small Missouri drugmaker recently raised the price of a 60-year-old antibiotic by more than 400 percent, in a move reminiscent of hedge-fund bad boy Martin Shkreli.